Biotest AG logo

BIO3 - Biotest AG News Story

€30 -0.1  -0.3%

Last Trade - 09/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.03bn
Enterprise Value £1.36bn
Revenue £420.2m
Position in Universe 387th / 1045

Takeda-led COVID-19 plasma treatment enters clinical trial with first patient

Fri 9th October, 2020 1:49am
TOKYO, Oct 9 (Reuters) - Japan's Takeda Pharmaceutical Co
 4502.T  said on Friday an alliance of drugmakers it spearheads
has enrolled its first patient in a global clinical trial of a
blood plasma treatment for COVID-19 after months of regulatory
delays.
    The phase 3 trial by the group, known as the CoVIg Plasma
Alliance, aims to enroll 500 adult patients from the United
States, Mexico and 16 other countries, according to a statement.
    Patients will be treated with Gilead Science Inc's  GILD.O 
Remdesivir alongside the plasma treatment, which will be
provided by CSL Behring, Takeda and two other companies.
    "We are hopeful that data from the clinical trial will be
available before the end of the year," Bill Mezzanotte, chief
medical officer of CSL Behring, said in the release.
    The group had aimed to begin the clinical trial in July, but
it was delayed pending regulatory approval. The National
Institutes of Health in the U.S. is the trial's sponsor.
 urn:newsml:reuters.com:*:nL4N2GE29X
    The alliance, which also includes Germany's Biotest AG
 BIOG.DE  and Octapharma Plasma, is working on a hyperimmune
globulin therapy derived from the blood plasma of people who
have recovered from COVID-19.
    It offers a standardised dose of antibodies and doesn't need
to be limited to patients with matching blood types.
 urn:newsml:reuters.com:*:nL3N2F02GB

 (Reporting by Rocky Swift; Editing by Kenneth Maxwell)
 ((rocky.swift@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.